Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

abciximab

Known as: 7E3, abciximab [Chemical/Ingredient], C7E3 
A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Background and Purpose— A previous randomized, placebo-controlled, double-blind study suggested that abciximab may be safe and… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients… Expand
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Background— Systematic use of coronary stents and optimized platelet aggregation inhibition has greatly improved the short-term… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
CONTEXT The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Background—Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND Glycoprotein IIb/IIIa blockers reduce procedure-related thrombotic complications of percutaneous coronary intervention… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
1997
Highly Cited
1997
BACKGROUND Blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab (a monoclonal-antibody Fab fragment directed… Expand
Is this relevant?
Highly Cited
1994
Highly Cited
1994
BACKGROUND Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of… Expand
Is this relevant?